SMARTc develops in solid tumors, innovative entities, such as second (i.e. stealth) and third (i.e. targeted) generation liposomes. These nanodrugs present an optimized pharmacokinetic profile, with a more specific distribution towards cancer cells and could offer patients a higher efficacy with lower toxicities than standard anticancer agents.
Third generation liposomes observed with TEM
In vitro cancer cells uptake
Efficacy tested on fluorescent and co-cultured spheroids
In vivo tumor uptake
Link articles :